Peter Schirmacher

Heidelberg University — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

108h-index61.7kcitations1.4kworks1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(151), Liver Disease Diagnosis and Treatment(129), Lung Cancer Treatments and Mutations(108), Cholangiocarcinoma and Gallbladder Cancer Studies(107), Lung Cancer Diagnosis and Treatment(95)

Publications1.4k total

Regulation of laboratory-developed tests and in-house in vitro diagnostic medical devices in the United States and the European Union—a comparative overview
ESMO Open·2025· 2 citedOpen Access
Supplementary Methods S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Table S3 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Table S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Figure S3 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Figure S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Table S2 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Table S6 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Table S7 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Table S5 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Figures S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Figures S2 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Supplementary Table S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
2025Open Access
Germany’s national genomDE strategy
Nature Medicine·2025· 2 cited
155eP Microcosting analysis of combined whole genome sequencing and whole transcriptome sequencing in cancer diagnostics
ESMO Open·2025Open Access
Metallothionein: a game changer in histopathological diagnosis of Wilson disease
Zeitschrift für Gastroenterologie·2025
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab – a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial)
BMJ Open·2025· 2 citedOpen Access
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome—a case for universal genetic testing?
ESMO Gastrointestinal Oncology·2025Open Access
CG>TG mutation frequency as negative predictor of homologous recombination deficiency in ovarian and breast cancer
Communications Biology·2025Open Access
page 1 of 71Next →

Frequent Co-authors

Thomas Longerich(10), Kai Breuhahn(9), Arndt Vogel(6), Albrecht Stenzinger(6), Wilko Weichert(6), Josep M. Llovet(5), Lars Zender(4), Arne Warth(4), Christoph Heining(4), Andrés Cervantes(3), Ian Chau(3), Bruno Daniele(3), Tim Meyer(3), Jean‐Charles Nault(3), Jens Ricke(3), Bruno Sangro(3), Chris Verslype(3), Francis Zech(3), Erika Martinelli(3), Esther Herpel(3)